Company Overview
Rein Therapeutics Inc. operates as a biopharmaceutical company dedicated to developing medicines that address unmet medical needs within specific orphan pulmonary and fibrosis indications in the United States. The firm focuses its research and development efforts on its lead product candidate, LTI-03, which is a peptide currently undergoing a Phase 1b clinical trial for the treatment of interstitial lung disease. This enterprise functions within the healthcare sector, specifically the biotechnology industry, an environment characterized by high capital expenditure requirements and significant regulatory scrutiny before products reach commercialization. As of the latest available data, the company holds a market capitalization of $35.05M, reports no annual revenue figures, and employs a staff of 11 individuals. These valuation and scale metrics indicate that Rein Therapeutics is a micro-cap entity in the early stages of development, where value is derived primarily from intellectual property and clinical trial progress rather than current sales or profit generation.
Financial Health
The company's financial statements reflect a typical pre-revenue biotechnology profile, with reported revenue (TTM) listed as N/A and a net income (TTM) of $-58,885,000, while EBITDA stands at $-23,768,000. The substantial negative net income relative to the EBITDA figure reveals a significant cost structure burden driven by non-cash expenses or specific accounting adjustments common in early-stage clinical trials, as there is no revenue to offset these costs. Free cash flow is reported at $-12,763,625, indicating that the company is burning cash to fund its operations and research initiatives, which limits its financial flexibility and necessitates ongoing capital raises or reliance on cash reserves. The balance sheet shows a cash position of $4.05M, with debt listed as N/A, suggesting the company is currently unleveraged and reliant on its cash pile to sustain operations. All three margins—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that indicates the company has not yet generated revenue to realize any profitability from its sales or operations. The current ratio is 0.90, which implies that the company's current liabilities slightly exceed its current assets, presenting a potential short-term liquidity challenge that must be managed through financing or operational efficiency improvements. Return on Equity is -83.3% and Return on Assets is -18.8%, metrics that reveal management is currently utilizing shareholder equity and company assets to generate losses rather than returns, a common but risky state for biotech firms in the development phase.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that standard earnings-based valuation models cannot be applied due to the absence of positive earnings, rendering comparisons with profitable peers impossible. The price-to-book ratio is 26.60, a figure that indicates the market is valuing the company at a significant premium over its net asset value, reflecting high expectations for the success of its clinical trials and the potential value of its intellectual property. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also cited as N/A or -3.13, suggesting that traditional multiple-based comparisons are not applicable given the lack of sales data and negative earnings. The stock has exhibited volatility within its trading range, with a 52-week high of $2.40 and a 52-week low of $1.02. Without the current price explicitly provided in the facts, the relative position cannot be calculated, but the range itself highlights the speculative nature of the investment vehicle. The beta value is 1.54, which means the stock's price volatility is expected to be 54% higher than the broader market, exposing investors to substantial price swings during periods of market turbulence.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, indicating that the company has not yet achieved a stage where year-over-year growth metrics are applicable due to the absence of consistent revenue streams. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available resources, including its limited cash reserves, back into research and development rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies that must fund expensive clinical trials to advance their pipeline toward market approval. The overall growth and income profile is characterized by a complete reliance on future potential rather than current income generation, with the company's value entirely dependent on the successful completion of its Phase 1b clinical trial for LTI-03 and the subsequent regulatory approval process.